全文获取类型
收费全文 | 15566篇 |
免费 | 1523篇 |
国内免费 | 946篇 |
专业分类
耳鼻咽喉 | 144篇 |
儿科学 | 157篇 |
妇产科学 | 283篇 |
基础医学 | 1961篇 |
口腔科学 | 265篇 |
临床医学 | 2064篇 |
内科学 | 2445篇 |
皮肤病学 | 174篇 |
神经病学 | 822篇 |
特种医学 | 556篇 |
外国民族医学 | 5篇 |
外科学 | 1850篇 |
综合类 | 2116篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 1023篇 |
眼科学 | 478篇 |
药学 | 1624篇 |
15篇 | |
中国医学 | 738篇 |
肿瘤学 | 1308篇 |
出版年
2024年 | 13篇 |
2023年 | 210篇 |
2022年 | 305篇 |
2021年 | 656篇 |
2020年 | 548篇 |
2019年 | 544篇 |
2018年 | 554篇 |
2017年 | 500篇 |
2016年 | 487篇 |
2015年 | 713篇 |
2014年 | 868篇 |
2013年 | 813篇 |
2012年 | 1162篇 |
2011年 | 1166篇 |
2010年 | 842篇 |
2009年 | 656篇 |
2008年 | 770篇 |
2007年 | 808篇 |
2006年 | 817篇 |
2005年 | 766篇 |
2004年 | 633篇 |
2003年 | 610篇 |
2002年 | 562篇 |
2001年 | 446篇 |
2000年 | 383篇 |
1999年 | 389篇 |
1998年 | 270篇 |
1997年 | 234篇 |
1996年 | 176篇 |
1995年 | 181篇 |
1994年 | 114篇 |
1993年 | 97篇 |
1992年 | 109篇 |
1991年 | 93篇 |
1990年 | 73篇 |
1989年 | 68篇 |
1988年 | 66篇 |
1987年 | 56篇 |
1986年 | 42篇 |
1985年 | 40篇 |
1984年 | 21篇 |
1983年 | 13篇 |
1981年 | 13篇 |
1980年 | 12篇 |
1979年 | 21篇 |
1976年 | 10篇 |
1974年 | 15篇 |
1973年 | 13篇 |
1972年 | 10篇 |
1969年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Hyun Cheol Chung MD PhD Yoon-Koo Kang MD PhD Zhendong Chen MD Yuxian Bai MD Wan Zamaniah Wan Ishak MD Byoung Yong Shim MD Young Lee Park MD Dong-Hoe Koo MD PhD Jianwei Lu MD Jianming Xu MD Hong Jae Chon MD Li-Yuan Bai MD Shan Zeng MD Ying Yuan MD Yen-Yang Chen MD Kangsheng Gu MD Wen Yan Zhong PhD Shu Kuang MD Chie-Schin Shih MD Shu-Kui Qin MD PhD 《Cancer》2022,128(5):995-1003
2.
Kim Jung Wan Eom Youngsub Park Wonkyung Song Jong Suk Jeong Ji Won Park Seh Kwang Kim Hyo Myung 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(10):3275-3283
Graefe's Archive for Clinical and Experimental Ophthalmology - To compare visual outcomes between two types of mix-and-match implanted trifocal extended-depth-of-focus (EDoF) and trifocal... 相似文献
3.
So Young Jeon Oh Eun Kwon Jin Woo Jang Sang Yoon Kang Jin-Young Min Sung Wan Kim 《Auris, nasus, larynx》2021,48(5):1031-1034
Stickler syndrome is a genetic disorder of connective tissue. One of the major symptoms associated with this disorder is an oro-facial malformation, which may cause a submucous cleft or a complete cleft of the hard palate. A 32-year-old man diagnosed with Stickler syndrome and a submucosal cleft palate (SMCP) visited our hospital with a chief complaint of excessive daytime sleepiness. The patient was diagnosed with severe obstructive sleep apnea (OSA), and administration of a polysomnography test revealed an apnea-hypopnea index (AHI) of 30.9 events/hour (h). Auto-titrating continuous positive airway pressure was initiated to control the OSA symptoms and subsequently the patient showed some improvement. However, due to continuous velopharyngeal insufficiency symptoms, intravelar veloplasty was performed. Three months after surgery, the AHI had decreased to 12.4 events/h. Recent studies have described a greater risk for OSA in individuals with cleft palate, than in the general population. The present case demonstrates surgical success in a patient with OSA and SMCP, suggesting that palatal surgery may be considered an optional surgical treatment for OSA patients with SMCP. 相似文献
4.
Tran Thi Hien Ines Ambite Murphy Lam Yim Wan Michele Cavalera Parisa Esmaeili Arunima Chaudhuri Samudra Sabari Marek Babjuk Catharina Svanborg 《International journal of cancer. Journal international du cancer》2023,153(3):584-599
Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer. 相似文献
5.
目的观察分析眼球钝挫伤合并外伤性晶状体脱位患者周边隐匿性视网膜病变的临床特点及预后。 方法本研究纳入2013年1月至2020年1月在柳州市人民医院眼科住院诊断为眼球钝挫伤合并外伤性晶状体脱位,并行23G微创玻璃体切割联合白内障摘除手术的72例(72眼)患者。根据裂隙灯和超声生物显微镜(UBM)检查,将患者分为晶状体不全脱位组和全脱位组,详细记录2组患者的术中周边视网膜病变情况,并分析其临床特征及疗效。 结果眼球钝挫伤合并外伤性晶状体脱位患者中有周边隐匿性视网膜病变的占72.22%,其中晶状体不全脱位组发生率高达80.95%,显著大于晶状体全脱位组的60.00%(P<0.05)。2组患者的周边隐匿性视网膜病变均以隐匿性视网膜裂孔、变性和出血为最常见。所有患者术后视网膜情况稳定,视力预后较好。 结论眼球钝挫伤合并外伤性晶状体脱位患者常出现周边隐匿性视网膜病变,最常见的是视网膜裂孔、出血、变性。23G微创玻璃体切割联合白内障摘除手术是有效治疗手段,具有创伤小、并发症少的优势。 相似文献
6.
Jie Ren Ying-Mu Tong Rui-Xia Cui Zi Wang Qing-Lin Li Wei Liu Kai Qu Jing-Yao Zhang Chang Liu Yong Wan 《World journal of gastrointestinal oncology》2020,12(12):1394-1406
BACKGROUNDDue to the special clinical features and biologic characteristics of adolescent and young adult (AYA) cancers, AYA cancers are different from cancers in children and elderly individuals. However, there are few reports on AYA hepatocellular carcinoma (HCC).AIMTo investigate the overall survival (OS) of AYA (15-39 years) and elderly (40-74 years) patients with HCC.METHODSThe data of all the HCC cases were extracted from the Surveillance, Epidemiology, and End Results database from 2004 to 2015 and were then divided into two groups based on age: AYA group (15-39 years) and older group (40-74 years). Kaplan-Meier curves and log-rank tests were used to compare the OS of the two groups. Propensity score matching (PSM) was employed to analyze the OS difference between the two groups. The Cox proportional hazards regression model was used to perform multivariate analysis to explore the risk factors for OS of HCC patients.RESULTSCompared to elderly cancer patients, AYA patients with HCC had a worse Surveillance, Epidemiology, and End Results stage, including the distant stage (22.1% vs 15.4%, P < 0.001), and a more advanced American Joint Committee on Cancer (AJCC) stage, including AJCC III and IV (49.2% vs 38.3%, P < 0.001), and were more likely to receive surgery (64.5% vs 47.5%, P < 0.001). Before PSM, the AYA group had a longer survival in months (median: 20.00, interquartile range [IQR]: 5.00-62.50) than the older group (median: 15.00, IQR: 4.00-40.00) (P < 0.001). After PSM, the AYA group still had a longer survival in months (median: 21.00, IQR: 5.00-64.50) than the older group (median: 18.00, IQR: 6.00-53.00) (P < 0.001). The Cox proportional hazards regression model showed that advanced age (hazard ratio [HR] = 1.405, 95%CI: 1.218-1.621, P < 0.001) was a risk factor for OS of HCC patients. In the subgroup analysis, the Cox proportional hazards regression model showed that in AJCC I/II HCC patients, advanced age (HR = 1.749, 95%CI: 1.352-2.263, P < 0.001) was a risk factor for OS, while it was not a risk factor in AJCC III/IV HCC patients (HR = 1.186, 95%CI: 0.997-1.410, P = 0.054) before PSM. After PSM, advanced age (HR = 1.891, 95%CI: 1.356-2.637, P < 0.001) was still a risk factor for OS in AJCC I/II HCC patients, but was not a risk factor for OS in AJCC III/IV HCC patients (HR = 1.192, 95%CI: 0.934-1.521, P = 0.157) after PSM.CONCLUSIONAYA patients with HCC have different clinical characteristics from older adults. In different AJCC stages, the two groups of patients have different OS: In AJCC I/II HCC patients, advanced age is a risk factor for OS, but it is not a risk factor for OS in the AJCC III/IV HCC patient group. 相似文献
7.
Guo-Chao Zhong Yang Peng Kang Wang Lun Wan You-Qi-Le Wu Fa-Bao Hao Jie-Jun Hu Hai-Tao Gu 《International journal of cancer. Journal international du cancer》2020,147(6):1577-1586
Epidemiological studies on magnesium intake and primary liver cancer (PLC) are scarce, and no prospective studies have examined the associations of magnesium intake with PLC incidence and mortality. We sought to clarify whether higher magnesium intake from diet and supplements was associated with lower risks of PLC incidence and mortality in the US population. Magnesium intake from diet and supplements was evaluated through a food frequency questionnaire in a cohort of 104,025 participants. Cox regression was employed to calculate hazard ratios for PLC incidence and competing risk regression was employed to calculate subdistribution hazard ratios for PLC mortality. Restricted cubic spline regression was employed to test nonlinearity. We documented 116 PLC cases during 1,193,513.5 person-years of follow-up and 100 PLC deaths during 1,198,021.3 person-years of follow-up. Total (diet + supplements) magnesium intake was found to be inversely associated with risks of PLC incidence (hazard ratiotertile 3 vs. 1: 0.44; 95% confidence interval: 0.24, 0.80; ptrend = 0.0065) and mortality (subdistribution hazard ratiotertile 3 vs. 1: 0.37; 95% confidence interval: 0.19, 0.71; ptrend = 0.0008). Similar results were obtained for dietary magnesium intake. Nonlinear inverse dose–response associations with PLC incidence and mortality were observed for both total and dietary magnesium intakes (all pnonlinearity < 0.05). In summary, in the US population, a high magnesium intake is associated with decreased risks of PLC incidence and mortality in a nonlinear dose–response manner. These findings support that increasing the consumption of foods rich in magnesium may be beneficial in reducing PLC incidence and mortality. 相似文献
8.
目的:探讨对携带BRCA1/2突变的中国健康女性实施乳腺预防性切除及I期重建的可行性。方法:选择2018年1月至2019年2月3例于北京大学国际医院就诊的携带BRCA1/2突变的中国健康女性,其中2例携带BRCA1突变、1例携带BRCA2突变,均有乳腺癌家族史,年龄为34~36岁,实施预防性保留乳头-乳晕的双侧乳腺切除和Ⅰ期假体重建术。结果:3例患者术后无并发症发生,术后中位随访时间为18个月,均无乳腺癌发生,对重建乳房外形满意,且焦虑和恐惧情绪显著下降,取得良好的疗效。结论:对携带BRCA1/2突变且有乳腺癌家族史的中国健康女性,在严格筛选的基础上,可慎重开展乳腺预防性切除及Ⅰ期重建术。 相似文献
9.
Jingliang Ye Junle Zhu Huairui Chen Jun Qian Lei Zhang Zhiping Wan Feng Chen Shuhan Sun Wen Li Chun Luo 《International journal of cancer. Journal international du cancer》2020,146(1):248-261
Brain glioma is the most common malignant tumor of the central nervous system, and one of the leading causes of death in patients with intracranial tumors. The clinical outcome of glioma is usually poor due to abundant vascularity, fast growth and susceptibility of invasion to normal brain tissues. Our microarray study showed that lncRNA-LINC01116 was significantly upregulated in glioma tissues and played an important role in cell proliferation, cycle, migration, invasion and angiogenesis. In addition, vascular endothelial growth factor (VEGFA) may be the major target genes in the downstream of lncRNA-LINC01116. Dual luciferase assay showed that LINC01116 and VEGFA both contained a miR-31-5p binding site, and LINC01116 could regulate the expression of VEGFA through competitive absorption of miR-31-5p. RNA immunoprecipitation indicated that LINC01116 and VEGFA were present in the miR-31-5p-RISC complex, and biotinylated miR-31-5p pull-down assay suggested that there was a competitive relationship between LINC01116 and VEGFA to bind with miR-31-5p. Collectively, our study has identified a novel lncRNA-LINC01116 and clarified the role and mechanism of LINC01116 in the tumorigenesis of glioma. LINC01116 may prove to be a potential target for the clinical diagnosis and treatment of glioma. 相似文献
10.
目的制备美洲大蠊Periplaneta americana口腔原位温敏凝胶。方法采用自由基聚合法首次以N-异丙基丙烯酰胺(NNIPAM)和甲基丙烯酸羟丙酯(HPMA)合成聚(N-异丙基丙烯酰胺-甲基丙烯酸羟丙酯)[P(NNIPAM-HPMA)]作为温敏材料;通过冷溶法制备美洲大蠊口腔原位温敏凝胶,采用Box-Behnken设计响应面法,以溶蚀时间、胶凝时间为评价指标,在固定美洲大蠊提取物用量基础上,对羟丙基甲基纤维素(HPMC)、聚乙烯吡咯烷酮(PVP K30)、P(NNIPAM-HPMA)的用量进行优选。结果通过原位聚合法合成了P(NNIPAM-HPMA)温敏材料;并用响应面法优选了可用于口腔的美洲大蠊原位温敏凝胶的处方,优选的处方为美洲大蠊提取物10%、HPMC 3.0%、PVP K30 9.5%、P(NNIPAM-HPMA) 10.0%,其溶蚀时间为2 h,胶凝时间8~9 s。结论优选得到美洲大蠊口腔原位温敏凝胶,为美洲大蠊提取物的口腔原位局部的临床应用奠定了科学依据。 相似文献